# Immunogenicity and Safety of Hecolin® in HIV Positive/Negative Adults and in Children

> **NCT06306196** · PHASE2 · RECRUITING · sponsor: **International Vaccine Institute** · enrollment: 1040 (estimated)

## Conditions studied

- Hepatitis E Virus Infection

## Interventions

- **BIOLOGICAL:** Hecolin® Recombinant Hepatitis E Vaccine
- **BIOLOGICAL:** Isotonic Sodium Chloride injection

## Key facts

- **NCT ID:** NCT06306196
- **Lead sponsor:** International Vaccine Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-04-04
- **Primary completion:** 2026-01
- **Final completion:** 2026-01
- **Target enrollment:** 1040 (ESTIMATED)
- **Last updated:** 2025-04-29

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06306196

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06306196, "Immunogenicity and Safety of Hecolin® in HIV Positive/Negative Adults and in Children". Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/clinical/NCT06306196. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*